Di Bartolomeo, M <br/><br/>
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.  [electronic resource] 

 -  Targeted oncology  Jun 2014 
 - 155-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1776-260X 
<br/><br/><label>Standard No.: </label>10.1007/s11523-013-0283-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>DNA Mutational Analysis<br/>Disease-Free Survival<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>GTP Phosphohydrolases--genetics<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Membrane Proteins--genetics<br/>Mutation<br/>Nuclear Proteins--genetics<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Tegafur--administration & dosage<br/>Transcription Factors--genetics<br/>Tumor Suppressor Protein p53--genetics<br/>Uracil--administration & dosage<br/>ras Proteins--genetics